Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05004454
Other study ID # BIO-2112
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 19, 2021
Est. completion date November 8, 2021

Study information

Verified date January 2023
Source BIO-CAT Microbials, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to investigate the effect of a novel Bacillus subtilis spore preparation on abdominal bloating, flatulence, and burping in healthy adults.


Description:

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. Examples of probiotic health benefits include the support of gastrointestinal health, immune health, and mood. Common probiotic strains include species from the genera Lactobacillus, Bifidobacterium, and Bacillus. Bacillus species are particularly well suited for probiotic applications because they are often manufactured as spores that persist without refrigeration and show survivability in the acidic conditions of the human gut. BIO-CAT Microbials' proprietary Bacillus subtilis BS50 strain ("BS50") has previously been shown in bacterial culture to secrete digestive enzymes and candidate gut microbiota-modulating molecules which may help support digestion and gastrointestinal health (unpublished data). BS50 also showed robust heat resistance and pH tolerance, which predicts strain survival across the wide pH range of the human gut. The objective of this clinical study is to investigate the effect of BS50 supplementation at 2x10⁹ CFU per day for 42 days on abdominal bloating, flatulence, and burping in healthy adults. This study will be a randomized, placebo-controlled, parallel design trial consisting of one screening visit (Visit 1) and two study visits (Visits 2 and 3). At Visit 1 (Day -7), subjects will arrive at the clinic in a fasting state. After subjects provide voluntary informed consent, subjects will undergo medical history, prior and current medication/supplement use, and inclusion and exclusion criteria assessments. Additionally, height, body weight, and vital signs will be measured and BMI will be calculated. Blood samples will be collected for chemistry and hematology analyses. Subjects will also be dispensed a paper Bowel Habits Diary with Bristol Stool Scale (BHD-BSS) and paper Gastrointestinal Tolerance Questionnaire (GITQ) with instructions to capture events occurring during the 7 continuous days prior to Visit 2 (Day 0). The GITQ contains a series of questions regarding the presence and severity of GI symptoms occurring during the past 24 h. At Visit 2 (Day 0), subjects will arrive at the clinic in a fasting state. Subjects will undergo clinic visit procedures (concomitant medication/supplement use, assess inclusion/exclusion criteria, body weight and vital signs measurements), and adverse event (AE) assessment. The paper BHD-BSS and GITQ will be collected and reviewed. To assess sleep quality and determine presence and duration of respiratory infection, subjects will be instructed to complete a paper Sleep Quality and Respiratory Infection Questionnaire (SQ-RIQ) in the clinic. Blood samples will be collected for assessment of markers of intestinal permeability, inflammation, and lipid profile. Subjects will be randomly assigned to a study product. Subjects will be dispensed their assigned study product and will be instructed to consume it once a day (1 capsule/d) for 42 days starting on Day 0. To assess sleep quality and determine presence and duration of respiratory infection, subjects will be dispensed a weekly electronic SQ-RIQ with instructions to complete this questionnaire weekly prior to Visit 3 (Day 42). Subjects will be dispensed the electronic BHD-BSS and electronic GITQ with instructions to capture events occurring daily leading up to Visit 3 (Day 42). At Visit 3 (Day 42), subjects will arrive at the clinic fasted and undergo clinic visit procedures (concomitant medication/supplement use, assess inclusion/exclusion criteria, body weight and vital signs measurements), and adverse event (AE) assessment. Blood samples will be collected for chemistry and hematology analyses as well as for assessment of markers of intestinal permeability, inflammation, and lipid profile.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date November 8, 2021
Est. primary completion date November 8, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female, 30-65 years of age, inclusive at Visit 1. - BMI of 18.0 to 31.9 kg/m², inclusive, at Visit 1. - Have =3 weekly total symptom score obtained by combining ratings for abdominal bloating, flatulence, and burping from the GITQ. - Consumes a typical American diet. Exclusion Criteria: - Abnormal laboratory test results of clinical significance at Visit 1. - Clinically important GI condition that would potentially interfere with the evaluation of the study product. - Recent (within 2 weeks of Visit 1) history of an episode of acute GI illness such as nausea/vomiting or diarrhea. - Self-reported history (within 6 weeks of Visit 1) of constipation or diarrhea. - Uncontrolled and/or clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including Type 1 and Type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including depression and/or anxiety disorders) or biliary disorders. - Uncontrolled hypertension as defined by the blood pressure measured at Visit 1. - Have received a COVID vaccine within 2 weeks of Visit 2 or expected to receive a COVID vaccine during the study period. - Had a positive SARS-CoV-2 test and experienced symptoms for >2 months. - History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer. - Weight loss or gain >4.5 kg in the 3 months prior to Visit 1. - Antibiotic use within 3 months of Visit 1 and throughout the study period. - Use of steroids within 1 month of Visit 1 and throughout the study period. - Chronic use (i.e., daily on a regular basis) of anti-inflammatory medications (e.g., NSAIDS) within 1 month of Visit 1. - Use of medications (over-the-counter or prescription) and/or dietary supplements, known to influence GI function.

Study Design


Intervention

Dietary Supplement:
Bacillus subtilis BS50 spore preparation
Subjects will consume 1 capsule containing 2x10? CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.
Maltodextrin
Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.

Locations

Country Name City State
United States Biofortis, Merieux Nutrisciences Addison Illinois

Sponsors (2)

Lead Sponsor Collaborator
BIO-CAT Microbials, LLC Biofortis Clinical Research, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Garvey SM, Mah E, Blonquist TM, Kaden VN, Spears JL. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. Gut Microbes. 2022 Jan-Dec;14(1):2122668. doi: 10.1080/1 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Abdominal bloating, flatulence, and/or burping Daily, 8-item Gastrointestinal Tolerance Questionnaire 6 weeks
Secondary Composite score of GI symptoms Abdominal bloating, flatulence, burping, nausea, vomiting, abdominal cramping, stomach rumbling, and reflux (Gastrointestinal Tolerance Questionnaire) 6 weeks
Secondary Individual GI symptoms scores other than abdominal bloating, flatulence, and burping Nausea, vomiting, abdominal cramping, stomach rumbling, and reflux (Gastrointestinal Tolerance Questionnaire) 6 weeks
Secondary Bowel function Stool frequency, stool consistency, straining and discomfort during bowel movement, sensation of incomplete evacuation (Bowel Habits Diary with Bristol Stool Scale) 6 weeks
Secondary Biomarkers of gut permeability Blood levels of zonulin, occludin, and lipopolysaccharide binding protein 6 weeks
Secondary Biomarkers of immune health Blood levels of C-reactive protein, IL-8, IL-6, IL-10, IFN-?, and TNF-a 6 weeks
Secondary Blood lipid profiling Blood levels of triglyceride, total cholesterol (total-C), LDL-C, and HDL-C 6 weeks
Secondary Incidence and duration of cold/flu/respiratory infection Weekly Sleep Quality and Respiratory Infection Questionnaire 6 weeks
Secondary Sleep quality Weekly Sleep Quality and Respiratory Infection Questionnaire 6 weeks
Secondary Safety - Adverse Events Self-reported adverse events at Visits 2 and 3 7 weeks
Secondary Safety - Blood Chemistry Profile Albumin, alkaline phosphatase, total bilirubin, calcium, chloride, creatinine, blood urea nitrogen, potassium, aspartate, aminotransferase, alanine aminotransferase, sodium, total protein, carbon dioxide, osmolality, and glucose 7 weeks
Secondary Safety - Blood Hematology Profile White blood cell count, red blood cell count, hemoglobin concentration, hematocrit (as volume percent), mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelet counts 7 weeks
See also
  Status Clinical Trial Phase
Completed NCT05986058 - Preliminary Efficacy of a Technology-based Physical Activity Intervention for Older Korean Adults During the COVID-19 Pandemic N/A
Completed NCT01235390 - Effects of the Consumption of California Walnuts on Cardiovascular Health Phase 1
Active, not recruiting NCT04811885 - The Effects of Covid-19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
Recruiting NCT05122689 - Dietary Inorganic Nitrate and the Enteral Microbiome N/A
Completed NCT03119792 - Salud Integral Colombia N/A
Completed NCT01767051 - Children Follow-up of PCOS Women N/A
Recruiting NCT05695586 - Effects of the Mindful Self-Compassion (MSC) Program N/A
Recruiting NCT06260579 - Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity N/A
Withdrawn NCT02202707 - Vasomotor Symptoms and Cardiovascular Control N/A
Active, not recruiting NCT04791618 - MECA Clinical Intervention ( MECA Health360x) N/A
Completed NCT03187704 - Boston Puerto Rican Health Study N/A
Completed NCT02453217 - The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial N/A
Recruiting NCT03090321 - MyHeart Counts Cardiovascular Health Study N/A
Completed NCT01293253 - Effect of Daily Stair Walking on Cardiovascular Health N/A
Active, not recruiting NCT03504059 - School-based Behavioural Intervention to Face Obesity and Promote Cardiovascular Health Among Spanish Adolescents N/A
Completed NCT01551355 - Promoting Heart Health in Preschool Children Phase 3
Recruiting NCT05887622 - The Potassium Supplementation Study N/A
Active, not recruiting NCT04121741 - Singing and Cardiovascular Health in Older Adults N/A
Completed NCT04715126 - Evaluate Efficacy of Oxyjun on Cardiovascular Health in Healthy Individuals. N/A
Completed NCT03467061 - The Effect of Dietary Nitrate on the Oral Microbiome N/A